AJP - Endocrinology and Metabolism, Vol 261, Issue 6 E725-E736, Copyright © 1991 by American Physiological Society

ARTICLES

Contribution of adrenergic mechanisms to glucose counterregulation in humans

P. De Feo, G. Perriello, E. Torlone, C. Fanelli, M. M. Ventura, F. Santeusanio, P. Brunetti, J. E. Gerich and G. B. Bolli
Istituto di Patologia Medica, Universita di Perugia, Italy.

To assess the role of adrenergic mechanisms during prolonged hypoglycemia, eight normal subjects were studied on six occasions. In study 1, insulin was infused subcutaneously (15 mU.m-2.min-1 for 12 h), and plasma glucose concentration (PG) decreased from 89 +/- 2 to 50 +/- 1 mg/dl. In study 2 (insulin as in study 1 + propranolol and phentolamine + variable glucose to maintain PG as in study 1), the rate of hepatic glucose production (HGO, [3-3H]glucose) was approximately 30% lower after 1.5 h, and the rate of peripheral glucose utilization (GU) was approximately 15% greater after 5 h. To quantitate the effects of adrenergic mechanisms on glucose counterregulation, in a control study (study 3), glucoregulatory hormone secretion was blocked, and the hormones were reinfused to reproduce study 1. When alpha- and beta-blockade plus variable glucose were superimposed to study 3 (study 4), HGO was approximately 25% lower (after 2 h), and GU was approximately 10% greater (after 6 h) vs. study 3. When glucose was not infused to match PG of study 3 (study 5), severe hypoglycemia developed (PG at 7 h 36 +/- 2 vs. 62 +/- 3 mg/dl). Finally, when glucose was not infused during alpha- and beta-blockade of study 2 (study 6), PG was 49 +/- 3 mg/dl at 7 h vs. 65 +/- 3 mg/dl of the control study (study 1), despite greater secretion of glucagon, growth hormone, and cortisol. It is concluded that adrenergic mechanisms play a key counterregulatory role, even in the presence of appropriate responses of glucagon and that greater increases in glucagon (and other counterregulatory hormones) cannot compensate fully for absent contribution of adrenergic mechanisms to counterregulation.

This article has been cited by other articles:

				Y. Koyama, P. Galassetti, R. H. Coker, R. R. Pencek, D. B. Lacy, S. N. Davis, and D. H. Wasserman Prior exercise and the response to insulin-induced hypoglycemia in the dog Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1128 - E1138. [Abstract] [Full Text] [PDF]

				R. P. Hoffman, C. A. Sinkey, J. M. Dopp, and B. G. Phillips Systemic and Local Adrenergic Regulation of Muscle Glucose Utilization During Hypoglycemia in Healthy Subjects Diabetes, March 1, 2002; 51(3): 734 - 742. [Abstract] [Full Text] [PDF]

				T. P.C. Monsod, W. V. Tamborlane, L. Coraluzzi, M. Bronson, T. Yong-Zhan Ma, and J. A. Ahern Epipen as an Alternative to Glucagon in the Treatment of Hypoglycemia in Children With Diabetes Diabetes Care, April 1, 2001; 24(4): 701 - 704. [Abstract] [Full Text]

				K. Hojlund, M. Wildner-Christensen, O. Eshoj, C. Skjarbak, J. J. Holst, O. Koldkjar, D. Moller Jensen, and H. Beck-Nielsen Reference intervals for glucose, {beta}-cell polypeptides, and counterregulatory factors during prolonged fasting Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E50 - E58. [Abstract] [Full Text] [PDF]